Kornimate/medical-research-clean huggingface dataset:
olanzapine in the treatment of patients with anorexia nervosa

Conditions: Anorexia Nervosa

Summary: the purpose of the study is to evaluate the efficacy of an anti-psychotic medication, olanzapine, in achieving desired weight gain in patients identified as having anorexia nervosa, either restricting or binge/purge subtype. the study will also evaluate the possible beneficial effects of olanzapine in reducing the severity of the obsessive and/or anxiety symptoms associated with this disorder.

the purpose of the study is to evaluate the efficacy of an anti-psychotic medication, olanzapine, in achieving desired weight gain in patients identified as having anorexia nervosa, either restricting or binge/purge subtype. the study will also evaluate the possible beneficial effects of olanzapine in reducing the severity of the obsessive and/or anxiety symptoms associated with this disorder.

Eligibility criteria:
inclusion criteria: * those who meet dsm iv criteria of anorexia nervosa- either restricting or binge/purge subtype exclusion criteria: * patients who are actively self destructive and/or suicidal * patients whose medical status is seriously compromised * patients whose eating disorder is superimposed on a major psychiatric disorder such as schizophrenia, major affective disorders, dissociative disorder or an active substance abuse disorder.

Keywords: pilot project, clinical trial, treatment outcome, psychopharmacology
oral health related quality of life

Conditions: Oral Health Related Quality of Life; Oral Disease

Summary: as oral health has a major impact on general health and quality of life, good oral health are essential. the aspects of oral health that are most important for each individual vary, and quality of life is subjective, and influenced by the person´s experiences, perceptions, expectations and ability to adapt to circumstances. fdi world dental federations definition of oral health is; "oral health is multifaceted and includes the ability to speak, smile, smell, taste, touch, chew, swallow, and convey a range of emotions through facial expressions with confidence and without pain, discomfort, and disease of the craniofacial complex.


Eligibility criteria:
inclusion criteria: read and understand swedish - exclusion criteria: -
assessment of pouch emptying with mri after roux-en-y gastric bypass

Conditions: Bariatric Surgery Candidate; Gastric Bypass; Obesity, Morbid; Pouch Emptying

Summary: a cross-sectional observational study in which pouch emptying rate is measured with mri in good (twl\>35%) and bad responders (twl\<25%) two years after laparoscopic roux-en-y gastric bypass (lrygb).


Eligibility criteria:
inclusion criteria: * women aged between 20 and 55 years * patients must be able to adhere to the study visit schedule and protocol requirements * patients must be able to give informed consent (ic) prior to any study procedures * patients who had a follow-up period up until two years after lrygb and have successful or unsuccessful weight loss. * willing to be informed about incidental findings of pathology and approving of reporting this to their general physician exclusion criteria: * diabetes mellitus * menopausal * gastrointestinal problems, gastric or intestinal diseases * drug or alcohol addiction * inability to stop smoking during the overnight fasting period * pregnant or lactating * having an intolerance or allergy for one of the components of the test product * inability to stop medications that affect gastrointestinal emptying like antisecretory drugs, narcotics and prokinetic agents * inability to stop medication that affects the motility of the upper gastrointestinal tract (anti-cholinergic drugs, prokinetics, theophylline, calcium blocking agents, opioids) * having a contra-indication to mri scanning (including, but not limited to): * pacemakers and defibrillators * intraorbital or intraocular metallic fragments * ferromagnetic implants
single and multiple ascending dose study of amg 513 in participants with obesity

Conditions: Cardiometabolic Disease

Summary: the primary objective of this study is to assess the safety and tolerability of amg 513 after single and multiple doses.


Eligibility criteria:
inclusion criteria: * participants in the study will be males and females 18 to 65 years of age at the time of signing the informed consent with a body mass index (bmi) between ≥ 30 kg/m\^2 and ≤ 40 kg/m\^2. * females enrolled must be of non-childbearing potential. exclusion criteria: * history and/or clinical evidence of diabetes mellitus, including hemoglobin a1c ≥ 6.5% and/or a fasting glucose of ≥ 126 mg/dl (7 mmol/l) at screening. * triglycerides ≥ 5.65 mmol/l (i.e., 500 mg/dl) at screening.

Keywords: amg 513 cardiometabolic disease
translation, cross-cultural validity and reliability of a danish version of the anterior knee pain scale

Conditions: Patella Subluxation; Patellofemoral Pain Syndrome

Summary: the anterior knee pain scale (kujala) is a questionnaire designed to assess adults with patellofemoral disorders and is widely used in both anterior knee pain and patellar dislocation patients.the questionnaire is a patient-reported outcome measure (prom), that was developed in 1993 and has been translated and validated into most major languages (e.g. french, italian, chinese, german, and spanish) and has gained wide international acceptance. in a recent systematic review, the kujala was among the eight most commonly used proms for patients with patellofemoral pain. in addition, the kujala was used in almost 80% of studies of patellofemoral instability/dislocation. the kujala has been widely used in denmark during the last 15 years, but surprisingly it has not been translated and validated in danish according to international guidelines. the translation of the kujala into danish will stimulate to more valid and precise results of the kujala questionnaire in both patients with anterior knee pain and patients with patellar dislocation the aim of this study is to cross-cultural translate and adapt the kujala into a danish kujala-dk. secondarily to determine validity and reliability of the kujala-dk in two consecutive danish populations of patients with either anterior knee pain or patellar dislocation.


Eligibility criteria:
inclusion criteria: * danish speaking * mpfl-reconstructed exclusion criteria: -

Keywords: mpfl kujala pain questionnaire translation
clinical management of antiplatelet drug resistance in patients with drug eluting coronary stents

Conditions: Coronary Artery Disease

Summary: it is recommended that patients who have drug-eluting stents placed in their coronary arteries take aspirin and plavix (clopidogrel) for at least a year. patients who stop taking these antiplatelet drugs or who have resistance to the antiplatelet effects of these drugs are at a higher risk of clots occurring inside the stents which may result in a heart attack. at the present time, it is unknown if increasing the doses of the antiplatelet agents is effective in overcoming this resistance. the purpose of this project is to identify patients with antiplatelet drug resistance and to test whether an increase in the plavix (clopidogrel) dose overcomes antiplatelet drug resistance.


Eligibility criteria:
inclusion criteria: * required coronary artery angioplasty with a drug-eluting stent deployment exclusion criteria: * the last drug-eluting stent placed greater than 2 weeks prior * aspirin or plavix (clopidogrel) allergy or contraindication

Keywords: drug eluting stents clopidogrel resistance aspirin resistance
efficacy and safety of ostenil® plus in the treatment of coxarthrosis

Conditions: Coxarthrosis

Summary: pmcf study to observe the routine application of ostenil® plus in the treatment of pain and restricted mobility in degenerative and traumatic changes of the hip joint.


Eligibility criteria:
inclusion criteria: 1. subjects ≥ 18 years of age and in good general health condition 2. signed informed consent 3. existing ostenil® plus recommendation for the treatment of coxarthrosis exclusion criteria: 1. known hypersensitivity to one of the ostenil® plus components 2. known pregnancy or lactating females 3. previous/concomitant participation in clinical investigation within the last 3 months prior to study inclusion 4. subjects not capable of contracting and of understanding the nature, risks, significance and implications of the clinical investigation and unable to form a rational intention in the light of these facts 5. subjects unable to understand informed consent or having a high probability of non compliance to the study procedures and / or non completion of the study according to investigator's judgement (e.g. illiteracy, insufficient knowledge of local language)
a study to assess the safety of grf6019 infusions in subjects with severe alzheimer's disease

Conditions: Severe Alzheimer Disease

Summary: this study will evaluate the safety, tolerability, and potential cognitive benefit of the experimental treatment grf6019 in subjects with severe alzheimer's disease.

this is a randomized, double-blind, placebo-controlled study to assess the safety, tolerability and potential cognitive benefit of grf6019, a human plasma protein fraction. grf6019 or placebo will be administered intravenously to subjects with severe alzheimer's disease every day for 5 consecutive days. the total study duration for each subject is approximately 9 weeks.

Eligibility criteria:
inclusion criteria: * diagnosis of probable ad according to the national institute on aging-alzheimer's association (nia-aa) criteria * mmse score 0-10 inclusive * modified hachinski ischemia scale (mhis) score of 4 or less * provided a signed and dated informed consent form (either the subject and/or subject's legal representative) exclusion criteria: * evidence of clinically relevant neurological disorder(s) other than probable ad * history of blood coagulation disorders or hypercoagulability; any concurrent use of an anticoagulant therapy. (e.g., heparin, warfarin, thrombin inhibitors, factor xa inhibitors). use of antiplatelet drugs (e.g., aspirin or clopidogrel) is acceptable. * unstable coronary heart disease, e.g. myocardial infarction or severe or unstable angina in the 6 months prior to dosing. * moderate to severe congestive heart failure (new york association class iii or iv). * poorly controlled high blood pressure (systolic blood pressure of 160 mmhg or higher and/or diastolic blood pressure of 100 mmhg or higher) despite treatment during the 3 months prior to dosing, or treatment refractory high blood pressure, defined as treatment requiring 3 or more antihypertensives from different classes. * prior hypersensitivity reaction to any human blood product or intravenous infusion; any known clinically significant drug allergy. * treatment with any human blood product, including transfusions and intravenous immunoglobulin, during the 6 months prior to screening. * history of immunoglobulin a (iga), haptoglobulin or c1 inhibitor deficiency; stroke, anaphylaxis, or thromboembolic complications of intravenous immunoglobulins. * hemoglobin \<10 g/dl in women; and \<11 g/dl in men.

Keywords: brain diseases nervous system diseases central nervous system diseases neurodegenerative diseases neurocognitive disorders mental disorders dementia tauopathy
steroids versus non-steroidal anti-inflammatory drugs following glaucoma surgery

Conditions: Glaucoma

Summary: this study aims to evaluate the eye pressure response to non-steroidal anti-inflammatory eye drops as compared to steroid eye drops following glaucoma surgery.

glaucoma is a chronic disease of the eye which results in gradual loss of nerve fibres, resulting in visual loss. the mainstay of treatment is reduction of intraocular pressure (iop), which has been shown to preserve vision, and glaucoma surgery aims to achieve this. one type of surgery involves insertion of a glaucoma drainage device (gdd). following surgery steroid eye drops are commonly used in order to reduce the inflammation that occurs as a result of the surgery. however, a common side effect of steroid eye drops is a rise in eye pressure. non-steroidal anti-inflammatory drugs (nsaid) eye drops do not have this side effect and are used as an alternative to steroids following other types of eye surgery. use of nsaid drops following gdd surgery may result in improved eye pressure. this study aims to evaluate the eye pressure response to nsaid eye drops following gdd surgery.

Eligibility criteria:
inclusion criteria: 1. 18 - 85 years of age 2. undergoing glaucoma drainage device surgery exclusion criteria 1. unable to consent 2. undergoing combined gdd and cataract surgery 3. patients with conditions requiring additional anti-inflammatory medications e.g., uveitic glaucoma, previous corneal transplant 4. patients with prior history of corneal ulceration 5. breast-feeding (nursing) mothers 6. pregnant or planning to become pregnant during the trial period 7. allergic to ketorolac tromethamine, or had an allergic-type reaction to acetylsalicylic acid or other non-steroidal anti-inflammatory drugs used for pain relief or arthritis

Keywords: intraocular pressure ahmed valve nsaids steroids
interstitial lung disease is a risk factor for cardiovascular disease

Conditions: Interstitial Lung Disease; Cardiovascular Morbidity

Summary: a group of interstitial pulmonary fibrosis will be recruited from assiut university hospital outpatient clinic. evaluation will be done regarding cardiovascular comorbidities (cardiovascular comorbidities will be evaluated with thorough assessment including; history, ecg, lipid profile and echocardiography). lipid profile, crp and kl-6 level will be assessed for recruited personnel. regression analysis will be used to identify risk factors for cardiovascular comorbidities among ipf patients.

interstitial lung disease (ild) is a chronic, progressive, parenchymal disease of the lungs. ild has been associated with various cardiovascular co-morbidities, such as coronary artery disease (cad) and heart failure (hf). so far, little is known regarding the cardiovascular co-morbidities in patients with idiopathic pulmonary fibrosis (ipf), the most aggressive form of ild. blood biomarkers have been shown to emerging evidence in patients with ipf in clinical practice. several blood biomarkers, including lung-epithelium specific proteins, chemokines, growth factors, proteases, and other serological markers, have been studied widely in the fields of diagnosis, disease severity, and prognosis in patients with ipf. among them, krebs von den lungen-6 (kl-6) is used in clinical practice and elevated level of kl-6 is known to predict mortality in patients with ipf. it is well documented that fibrosis is closely linked to the inflammatory response. emerging evidence suggests that cardiac fibrosis in general is primarily due to complications associated with acute and prolonged inflammation, suggesting that even low-grade, persistent inflammation is enough to promote cardiac fibrosis. the cellular and molecular events that underpin the inflammatory processes in cardiac disease are complex and poorly understood, with many tissue and disease specific mechanisms.

Eligibility criteria:
inclusion criteria: * patients diagnosed as interstitial pulmonary fibrosis exclusion criteria: * patients refusing to participate in the study
a phase 3 study evaluating safety and effectiveness of immune globulin intravenous (igiv 10%) for the treatment of mild-to-moderate alzheimer´s disease

Conditions: Alzheimer´s Disease

Summary: the purpose of this study was to evaluate the efficacy and safety of 2 doses of immune globulin intravenous (igiv), 10% administered every 2 weeks as an intravenous (iv) infusion compared with placebo in participants with mild to moderate alzheimer's disease (ad).

study visits: each participant will be tested at the investigational site, and if qualified, will be treated intravenously (through a vein) every two weeks for 70 weeks (approximately 18 months). the first three infusions must be done at the site, but if the infusions are well tolerated, subsequent infusions may be done by a qualified healthcare provider in the home or other suitable location. each participant must return to the site every 3 months for evaluation of cognition as well as blood tests and scans of the brain.

Eligibility criteria:
main inclusion criteria: * written informed consent - participant (or participant´s legally acceptable representative) and caregiver who are willing and able to participate for the duration of the study * diagnosis of probable alzheimer´s disease (ad) * dementia of mild to moderate severity defined as mini-mental state examination (mmse) 16-26 inclusive at the time of screening * neuroimaging (computed tomography \[ct\] or mri) performed after symptom onset consistent with ad diagnosis * ability to comply with testing and infusion regimen, including fluency in english or spanish, adequate corrected visual acuity and hearing ability * on stable doses of regulatory authority approved ad medication(s) for at least 3 months prior to screening. these medications must be continued throughout this study. * if receiving psychoactive medications (e.g. antidepressants other than monoamine oxidase inhibitors (maois) and most tricyclics, antipsychotics, anxiolytics, anticonvulsants, mood stabilizers, etc), must be on stable doses for at least 6 weeks prior to screening main exclusion criteria (reasons why it might not be appropriate to participate): * any other forms of dementia * medical issues that might increase the risk of treatment with igiv, 10%, such as: 1. significant problems with blood pressure, heart disease, clotting disorders, strokes or recent heart attacks 2. evidence of current bleeding in the brain by mri 3. serious problems with the liver or kidneys 4. allergies to blood products * medical issues that might interfere with the evaluation of the treatment of dementia or might make dementia worse, such as: 1. diabetes 2. recent treatment with chemotherapy or immune suppression 3. the recent use of other investigational drugs, especially antibody therapy for ad 4. severe headaches or psychiatric problems

Keywords: alzheimer´s dementia dementia of alzheimer type immunoglobulins gammaglobulins immune globulin intravenous (igiv) intravenous immune globulin (ivig) antibodies amyloid immunotherapy
a study to assess change in disease state in adult participants with acute myeloid leukemia (aml) ineligible for intensive chemotherapy receiving oral venetoclax tablets in canada

Conditions: Acute Myeloid Leukemia

Summary: acute myeloid leukemia (aml) is a cancer of the blood and bone marrow and is the most common acute leukemia in adults. this study will evaluate how well venetoclax works to treat aml in adult participants who are ineligible for intensive induction chemotherapy in canada. venetoclax is a drug approved to treat acute myeloid leukemia (aml). all study participants will receive venetoclax as prescribed by their study doctor in accordance with approved local label. adult participants with a new diagnosis of aml who are ineligible for intensive induction chemotherapy will be enrolled. around 200 participants will be enrolled in the study in approximately 15-20 sites in canada. participants will receive venetoclax tablets to be taken by mouth daily according to the approved local label. the duration of the study is approximately 36 months. there is expected to be no additional burden for participants in this trial. all study visits will occur during routine clinical practice and participants will be followed for 36 months.


Eligibility criteria:
inclusion criteria: * diagnosis of acute myeloid leukemia (aml). * ineligible for intensive chemotherapy, determined by the physician's assessment of age, eastern cooperative oncology group performance status (ecog-ps), comorbidities, regional guidelines, and institutional practice. * participant for whom the physician has decided to initiate venetoclax treatment in accordance with the local label. the decision to treat with venetoclax is made by the physician prior to any decision to approach the participant to participate in this study. exclusion criteria: - participation in an interventional clinical trial within 30 days prior to venetoclax treatment initiation.

Keywords: acute myeloid leukemia venetoclax venclexta venclyxto abt-199 cancer
free fluid detection with telementored efast

Conditions: Hemoperitoneum; Ascites; Intra-Abdominal Fluid Collection; Postoperative Complications

Summary: this feasibility study will evaluate the accuracy of telementored efast (extended focused assessment with sonography in trauma) in detecting abdominal free fluid in patients who have recently undergone liver surgery. the primary goal is to determine how well the remote-guided ultrasound can identify fluid accumulation compared to conventional ultrasound performed by a radiologist. participants in this study will be examined with ultrasound, supported in real-time by a remote expert, to assess its accuracy and other relevant performance metrics.

the study is designed as a prospective diagnostic trial and involves 40 patients at oslo university hospital. participants will receive an ultrasound examination shortly after surgery, where a nurse is guided in real-time by a remote expert via teleultrasound. the primary objective is to assess the agreement between the telementored efast examination and a conventional ultrasound performed by an on-site radiologist. in addition to diagnostic accuracy, the study will evaluate various performance metrics, including the duration of the telementored versus conventional examinations, network reliability, and cognitive workload using the nasa task load index. the study will also explore the learning curve associated with telementored efast by monitoring the improvement in examination efficiency over time. these metrics will help determine the feasibility of using telementored ultrasound as a reliable diagnostic tool in postoperative care, potentially reducing the need for more resource-intensive imaging modalities and improving patient outcomes through timely decision-making.

Eligibility criteria:
inclusion criteria: patients who have undergone laparoscopic liver surgery at the oslo university hospital and are within 72 post-surgery exclusion criteria: allergy to ultrasound gel. patients colonized with esbl, mrsa and vre will be excluded due to infection control. significant postoperative pain that can exacerbated by probe pressure.

Keywords: teleultrasound efast telemedicine ultrasound